T. Rowe Price Associates
ABEO icon

T. Rowe Price Associates’s Abeona Therapeutics ABEO Stock Holding History

T. Rowe Price Associates’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Buy
32,591
+1,586
+5% +$8.71K ﹤0.01% 3003
2026
Q1 		$139K Buy
31,005
+6,878
+29% +$34.4K ﹤0.01% 2935
2025
Q4 		$128K Buy
24,127
+969
+4% +$4.88K ﹤0.01% 2913
2025
Q3 		$123K Buy
23,158
+1,249
+6% +$7.92K ﹤0.01% 2890
2025
Q2 		$125K Buy
+21,909
New +$125K ﹤0.01% 2849
2021
Q4 		– Sell
-976
Closed -$27K – 2974
2021
Q3 		$27K Buy
+976
New +$31.3K ﹤0.01% 2924
2019
Q2 		– Sell
-100,134
Closed -$18.4M – 2542
2019
Q1 		$18.4M Sell
100,134
-1,848
-2% -$330K ﹤0.01% 1198
2018
Q4 		$18.2M Sell
101,982
-39,239
-28% -$8.56M ﹤0.01% 1172
2018
Q3 		$45.2M Sell
141,221
-8,763
-6% -$3.11M 0.01% 951
2018
Q2 		$60M Buy
149,984
+96,537
+181% +$42.2M 0.01% 823
2018
Q1 		$19.2M Buy
53,447
+24,077
+82% +$8.95M ﹤0.01% 1200
2017
Q4 		$11.6M Buy
29,370
+21,011
+251% +$8.69M ﹤0.01% 1312
2017
Q3 		$3.56M Buy
+8,359
New +$2.25M ﹤0.01% 1479

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates's ABEO Position: Q2 2026 in Review

T. Rowe Price Associates increased its Abeona Therapeutics (ABEO) stake by 5.1% in Q2 2026, buying an estimated $8.71K and bringing the position to 32,591 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #3003.

T. Rowe Price Associates first reported a position in ABEO in Q3 2017 and has held it in 13 quarters since. The position peaked at $60M in Q2 2018. 127 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • T. Rowe Price Associates held 32,591 shares of Abeona Therapeutics worth $202K as of Q2 2026.
  • T. Rowe Price Associates bought 1,586 Abeona Therapeutics shares in Q2 2026, an estimated $8.71K.
  • Abeona Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3003 holding.
  • T. Rowe Price Associates first reported a position in Abeona Therapeutics in Q3 2017 and has held it in 13 quarters since.
  • T. Rowe Price Associates's Abeona Therapeutics position peaked at $60M in Q2 2018.
  • 127 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.